所系名称 营养科学研究所
性别 女
专业名称 生物化学与分子生物学
技术职务 研究员
行政职务 研究组长
Mail地址 huiwang@sibs.ac.cn
通讯地址 上海市太原路294号
邮政编码 200031
| 研究方向 | 分子营养药学与毒理学 | ||||
| 研究工作 | 营养药学、应用药学、药物遗传学、基因组学及代谢组学的研究；原癌基因的调控与沉默－机制的研究及其在新药研发中的应用；基于RNA/DNA的生物工程－高新技术及其在新药研发中的应用；肿瘤微环境与机体相互作用机制的研究及其在新药研发中的应用；新型癌症早期检测手段的研究与应用；新型肿瘤免疫调节剂的研究与应用；天然产物中肿瘤治疗与预防性药物的研究与应用；肿瘤分子流行病学的研究；胚胎早期发育的分子调控；食品安全快速检测新技术、新方法的研究与开发；食品中有毒有害物质危害作用机制的研究。 | ||||
| 获奖情况 | 1) 入选中国科学院“百人计划”称号(2007)。 2) 获上海市优秀女青年科技工作者成才资助金 (2007)。 3) 中国营养学会年会优秀论文奖 (2006)。 4) 获美国临床药理和药物学会理事长奖(American Society of Clinical Pharmacology and Therapeutics，ASCPT)，并被邀请作大会发言 (2000)。 5) 被提名为UAB国际学者奖最终候选人(2000)。 6) 国际肿瘤预防学会 (International Society of Preventive Oncology，ISPO) 青年学 者奖获得者，并在该学会举办的瑞士日内瓦年会上获得优秀论文奖 (2000)。 7) 被录入国际专业人士名人录 (2000)。 8) 天津市科技成果一等奖 (排名第一) (1999)。 | ||||
| 个人简介 | 王慧，博士，研究员，博士生导师。1999年在天津医科大学/美国伯明翰阿拉巴马大学(UAB)获得医学、理学博士学位(中美联合培养)；1999年至2001年在UAB大学做博士后研究；2001年至2002年任UAB大学临床药理学、药理与毒理学讲师；2002年至2005年任助理教授、UAB癌症研究中心副研究员及医学院癌症药理学中心实验室副主任；2005年10月至今任中国科学院上海生科院营养所研究员、研究组长(PI)、食品安全研究中心主任、复旦大学兼职教授。申请人长期从事肿瘤信号转导通路及肿瘤预防治疗、人群基因易感性及早期诊断、环境有毒物质作用机制及其快速检测技术研发，在新药的药理和毒理评价领域具有丰富经验，在疾病预防控制、早期诊断及靶向治疗的基础和应用研究中成绩突出，重视学科交叉渗透及多学科综合研究，是2000年美国临床药理和药物学会理事长奖和2000年国际肿瘤预防学会青年学者奖获得者。至今，在PNAS、Cancer Res、JBC、Oncogene、Clin Cancer Res、Mol Cancer Ther 等国际期刊上发表研究论文72篇（其中SCI收录论文56篇、被引用907次），参编书籍3部；国际学术会议大会邀请报告2次；申请国内外专利5项（美国3项、中国2项）；为国际期刊Cancer Res、Clin Cancer Res、Mol Cancer Ther 等的审稿人，为美国国立卫生院癌症研究所(NCI)提交20多个用于新药开发的保密性总结报告；为美国癌症研究协会（AACR）和中国细胞生物学学会（CSCB）和中国生物化学与分子生物学学会（CSBMB）会员；申请国内外专利5项。2006年入选上海市“浦江人才计划”；2007年入选中国科学院“百人计划”，获教育部留学回国人员科研启动基金，上海市科委“白玉兰计划”资助，并获得上海市优秀女青年科技工作者成才资助金。目前承担科技部重大科学研究计划项目及上海市科委重大攻关项目，同时还与政府、企业合作，承担多项药品、保健品、功能性食品以及食品安全检测开发项目。 | ||||
| 近期论文 | 1.Hou J, Wang D, Zhang R, and Wang H*. Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action. Clin Cancer Res. 2008 accepted (*通讯作者) 2.Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, and Wang H*. Association of Common PALB2 Polymorphisms with Breast Cancer Risk: a Case-Control Study. Clin Cancer Res. 2008. in press (*通讯作者) 3.Chen T, Li M, Zhang R, and Wang H*. Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy. J Cell Mol Med. 2008 May 2. (*通讯作者) 4.陈涛, 陈露, 王慧*. Survivin在卵巢癌的研究进展. 国际妇产科学杂志, 2008, in press. (*通讯作者) 5.Wang W, Wang H*, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer: activity in vitro and in vivo and mechanisms of action. Br J Cancer. 2008 Feb 26;98(4):792-802. (*共同第一作者及通讯作者) 6.Wang W, Rayburn ER, HaoM, Zhao Y, Hill DL, Zhang R, Wang H*. Experimental Therapy of Prostate Cancer with Novel Natural Product Anti-cancer Ginsenosides. Prostate. 2008; Mar 6; [Epub ahead of print]. (*通讯作者) 7.Saif MW, Sellers S, Li M, Wang W, Cusimano L, Wang H, Zhang R. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2007 Nov; 60(6):871-82. 8.Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H*, Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 2007 Aug 2;26(35):5029-37. (*通讯作者) 9.Rayburn E, Wang W, Zhang R., Wang H*. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Intl J Oncol. 2007 Jun;30(6):1511-9. (*通讯作者) 10.He J, Zhou F, Shao K, Hang J, Wang H, Rayburn E, Xiao Z, Lee SW. Xue Q, Feng X, Shi S, Zhang C, Zhang S. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer. 2007 Apr; 56(1):51-58. 11.Wang W, Zhao Y, Rayburn E, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chem Pharm. 2007 Apr;59(5):589-601. 12.Wang H*, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Intl J Oncol. 2007 Apr; 30(4):947-53. (*通讯作者) 13.Wang H, Li M, Lin W, Wang W, Zhang Z, Rayburn E, Lu J, Chen D, Yue X, Shen F, Jiang F, He J, Wei W, Zeng X. Zhang R. Extracellular activity of cAMP-dependent protein kinase (ECPKA) as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Can Epidem Biomarker Prev. 2007 Apr; 16(4):789-95. 14.Li M, Zhang Z, Hill DL, Wang H, Zhang R. Curcumin, a dietary component, has anti-cancer, chemosensitization and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3 kinase/mTOR/ETS2 pathway. Cancer Res. 2007 Mar 1;67(5):1988-96. 15.Zhao Y, Wang W, Rayburn E, Hill DL, Wang H, Zhang R. Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng. Med Chem. 2007;3:51-60. 16.Rayburn E, Wang W, Zhang Z, Li M, Kandimalla ER, Agrawal S, Zhang R, Wang H*. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate. 2006 Nov 1;66(15):1653-63. (*通讯作者) 17.Wang Z, Wang H, Rhie JK, Covey JM, Liang P, Wang S, Wang C, Hu Y, Prasad G, Nan L, Hill DL, Zhang R. Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal. 2006 Sep 18; 42(2):272-6. 18.LaCasse EC, Cherton-Horvat GG, Hewitt KE, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM640, a second generation antisense oligonucleotide targeting XIAP. Clin Cancer Res. 2006 Sep 1; 12(17):5231-41. 19.Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anti-cancer activity and potentiation of antibody therapy. Mol Cancer Therapeutics. 2006 Aug; 5(8):2106-14. 20.Zhang R and Wang H. Antisense strategies for the development of novel cancer therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. Novel Anticancer Agents Strategies for Discovery and Clinical Testing. Elsevier Science, New York, NY. 2006; pp 193-206. 21.Li M, Wang H*, Hill DL, Stinson S, Veley K, Grossi I, Peggins J, Covey JM, Zhang R. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Cancer Chemother Pharm.. 2006;57(5):607-614. (*通讯作者) 22.Rayburn ER, Wang H, Zhang R. Antisense-based cancer therapeutics: are we there yet? Expert Opinion on Emerging Drugs. 2006;11(2):337-52. 23.Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting TLR9. Mol Cancer Ther. 2006; 5(6):1585-92. 24.Zhang Z, Wang H, Li M, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005 Nov 3;24(48):7238-47. 25.Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann N Y Acad Sci. 2005 Nov; 1058: 205-14. 26.Li M, Zhang Z, Hill D, Chen X, Wang H, Zhang R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 2005 Sep 15;65(18):8200-8. 27.Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer Therapy (part I): Growth factors and protein tyrosine kinases. Am J Pharmacogenomics. 2005; 5(3):173-90. (*通讯作者) 28.Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules. Am J Pharmacogenomics. 2005; 5(4):247-57. (*通讯作者) 29.Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer therapy ((Part III): Transcription. Am J Pharmacogenomics. 2005; 5(5):327-38. (*通讯作者) 30.Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer therapy (Part IV): Regulators of the cell cycle, DNA damage repair and apoptosis. Am J Pharmacogenomics. 2005; 5(6):397-407. (*通讯作者) 31.Wang H, Rayburn E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anti-cancer therapeutics. Curr Pharm Des. 2005 Aug;11(22):2889-907. 32.Wang H*, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, Hill DL. Preclinical pharmacology of 2-Methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharm. 2005 May 10;56(3):291-8. (*通讯作者) 33.Wang H*, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL. Preclinical pharmacology of Epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharm. 2005 May 3;56(3):255-60. (*通讯作者) 34.Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol. 2005 Apr; 56(2):182-8. 35.Zhang R, Wang H, Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: Proof of principle, in vitro and in vivo activities, and Mechanisms. Curr Cancer Drug Targets. 2005 Feb; 5(4):43-50. 36.Rayburn E, Zhang R, He J, Wang H*. MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005 Feb; 5(1):27-42. (*通讯作者) 37.Rayburn E, Wang H, He J, Zhang R. RNA silencing technologies in drug discovery and target validation. Letters in Drug Design and Discovery. 2005 Feb; 2(1):1-18. 38.Rayburn E, Wang W, Zhang R, and Wang H*. Antisense approach in drug discovery and development. Prog Drug Res. 2005; 63:227-74. (*通讯作者) 39.Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W, He TC. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004 Dec; 4(8):653-71. 40.Prasad G, Wang H, Hill DL, Zhang R. Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem-Anti-Ca Agents 2004 Jul; 4(4):347-61. 41.Wang H, Li M, Rinehart JJ, Zhang R. Dexamethasone as a chemoprotectant in cancer chemotherapy: Hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharm 2004 Jun; 53(6):459-67. 42.Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21(WAF1/CIP1), independent of p53. J Biol Chem. 2004 Apr; 279(6):16000-6. 43.Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: in vivo activity, pharmacokinetics and clinical implications for cancer chemotherapy. Clin Cancer Res. 2004 Mar; 10(5):1633-44. (Featured article) 44.Zhang Z*, Wang H*, Prasad G*, Li M, Yu D, Bonner J, Agrawal S, Zhang R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res. 2004 Feb 15; 10(4):1263-73. (*共同第一作者) (Featured article) 45.Zhang R, Wang H. Antisense technology. In: D. T. Curiel and J.T. Douglas: Contemporary Cancer Research: Cancer Gene Therapy. Humana Press, Totowa, NJ, 2004; pp 35-49. 46.Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Chemosensitization and radiosensitization of human cancer by antisense Anti-MDM2 Oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci. 2003 Dec; 1002: 217-35. 47.Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11636-41. 48.Zhang R and Wang H. Antisense oligonucleotides targeting RIa subunit of protein kinase A; in vitro and in vivo antitumor activity and pharmacokinetics. Methods Mol Med. 2003; 75: 637-54. 49.Zhang R and Wang H. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol Med. 2003; 85: 205-22. 50.Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang P, Zhang R, Agrawal S. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 1; 31(9):2393-400. 51.Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate. 2003 Feb 15; 54(3):194-205. 52.Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER, Zhang R, Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Comm. 2003 Jan 24; 300(4):853-61. 53.Zhang R and Wang H. Modulation of gene expression by antisense oligonucleotides. In: S. W. Kim and R.I. Mahato eds: Pharmaceutical Perspectives of Nucleic acid-based Therapeutics. Taylor & Francis: London, UK. 2002;pp33-53. 54.Yu D, Zhu F, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Comm. 2002 Sep; 297(1):83-90. 55.Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002 Jul; 21(1):73-80. 56.Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, Zhang R, Hill DL. Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta- D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol. 2002 May; 49(5):419-24. 57.Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int J Oncol 2002 Apr; 20(4):745-52. 58.Prasad G, Wang H, Agrawal S, Zhang R. Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res. 2002 Apr; 22:107-16. 59.Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor efficacy of a novel antisense anti-mdm2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med.2002 Apr; 8(4):185-99. 60.Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res. 2001 Nov; 7(11):3613-24. 61.Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets. 2001 Nov; 1(3):177-96. 62.Zhang R, Wang H. MDM2 Oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000 Mar;6(4):393-416. 63.Zhang R, Wang H. Antisense oligonucleotides as anticancer therapeutics. Recent Research Development in Cancer. 2000; 2:61-76. 64.Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int J Oncol.1999 Oct; 15(4):653-60. 65.Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIa subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA. 1999 Nov 23; 96(24):13989-94. | ||||
